Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
AMGEN (AMGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, AMGEN's actual EPS was $6.02, beating the estimate of $5.39 per share, resulting in a 11.64% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
